Thane Wettig is recorded as Board Member and CEO at Kyntra Bio, Inc. (KYNB). The newest filing on record that lists Thane Wettig as Board Member and CEO at Kyntra Bio, Inc. (KYNB) is dated April 27, 2026. Kyntra Bio, Inc. reported in an 8-K filed October 6, 2023 that Thane Wettig was appointed member of the Board, effective October 2, 2023. Kyntra Bio, Inc. reported in an 8-K filed October 6, 2023 that Thane Wettig was appointed Chief Executive Officer, effective October 2, 2023. The proxy statement of Kyntra Bio, Inc. reports total compensation of $3,640,829 for Thane Wettig in fiscal 2023, including a base salary of $573,334. Disclosed compensation is on record for 6 fiscal years. Thane Wettig has spoken on 6 earnings calls across 1 company, most recently for Kyntra Bio, Inc. on August 13, 2026. Kyntra Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kyntra Bio, Inc. includes James A. Schoeneck (CEO), Thomas B. Neff (CEO), Jim Schoeneck (Chairman) and 3 others.
“On October 2, 2023, the Board of Directors (the "Board") of FibroGen, Inc. (the "Company") appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.”
Kyntra Bio, Inc. Form 8-K, filed October 6, 2023
· Read the filing
“On October 2, 2023, the Board of Directors (the "Board") of FibroGen, Inc. (the "Company") appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.”
Kyntra Bio, Inc. Form 8-K, filed October 6, 2023
· Read the filing
Thane Wettig on recent calls
“On today's call, I will provide an update on the important progress we have made across our clinical portfolio.”
“Today, I will provide an update on our efforts focusing on our three main priorities: completing the sale of FibroGen China, progressing with our lead asset, FG-3246, a potential first-in-class antibody drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer, and the path forward for…”
“On today's call, I will provide an update on our ongoing efforts to transform FibroGen with a focus on our three main priorities: the sale of FibroGen China; the advancement of our lead asset, FG-3246, a potential first-in-class antibody drug conjugate targeting CD46 and its companion PET imaging agent in metastatic…”
